FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153979476> ?p ?o ?g. }

• W2153979476 endingPage "999" @default.
• W2153979476 startingPage "993" @default.
• W2153979476 abstract "BackgroundThis phase II, open-label study evaluated the efficacy and safety of erlotinib as second-line therapy in non-small-cell lung cancer (NSCLC) patients with brain metastases (BM).Patients and methodsForty-eight patients aged 18–75 years with Eastern Cooperative Oncology Group performance status 0–2, confirmed adenocarcinoma or activating epidermal growth factor receptor (EGFR) mutation-positive NSCLC, and asymptomatic BM without extracranial progressive disease after first-line platinum-doublet chemotherapy were recruited. Treatment comprised erlotinib 150 mg/day. The primary end point was progression-free survival (PFS) determined by RECIST.ResultsThe median PFS was 10.1 months [95% confidence interval (CI) 7.1–12.3] for intracranial progression and 9.7 months (95% CI 2.5–17.8) for intracranial and systemic progression. Patients with EGFR mutation-positive disease had significantly longer median PFS versus EGFR wild-type disease [15.2 months (95% CI 8.3–22.2) versus 4.4 months (95% CI 0.0–11.6); P = 0.02]. The median overall survival was 18.9 months (95% CI 14.4–23.4); 6-month and 1-year survival rates were 85% and 73%, respectively. Overall response rate was 58.3%. Most common adverse events were rash (77.1%), paronychia (20.8%), hyperbilirubinemia (16.7%), and diarrhea (14.6%); these were predominantly of grade 1/2.ConclusionsSingle-agent erlotinib was active and well tolerated in NSCLC patients with BM. Further studies are warranted." @default.
• W2153979476 created "2016-06-24" @default.
• W2153979476 creator A5004598929 @default.
• W2153979476 creator A5004928583 @default.
• W2153979476 creator A5006820907 @default.
• W2153979476 creator A5016049048 @default.
• W2153979476 creator A5019805104 @default.
• W2153979476 creator A5038306289 @default.
• W2153979476 creator A5043568223 @default.
• W2153979476 creator A5046162972 @default.
• W2153979476 creator A5047219755 @default.
• W2153979476 creator A5057704753 @default.
• W2153979476 creator A5074092905 @default.
• W2153979476 date "2013-04-01" @default.
• W2153979476 modified "2023-10-01" @default.
• W2153979476 title "Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG–0803)" @default.
• W2153979476 cites W1974784556 @default.
• W2153979476 cites W1994730720 @default.
• W2153979476 cites W2013070755 @default.
• W2153979476 cites W2017045345 @default.
• W2153979476 cites W2018652673 @default.
• W2153979476 cites W2021999460 @default.
• W2153979476 cites W2026524394 @default.
• W2153979476 cites W2040181388 @default.
• W2153979476 cites W2043826980 @default.
• W2153979476 cites W2046238840 @default.
• W2153979476 cites W2050368070 @default.
• W2153979476 cites W2057961038 @default.
• W2153979476 cites W2060254075 @default.
• W2153979476 cites W2073819958 @default.
• W2153979476 cites W2090615329 @default.
• W2153979476 cites W2093614047 @default.
• W2153979476 cites W2100912832 @default.
• W2153979476 cites W2115091425 @default.
• W2153979476 cites W2124224831 @default.
• W2153979476 cites W2124729820 @default.
• W2153979476 cites W2128688922 @default.
• W2153979476 cites W2128871519 @default.
• W2153979476 cites W2129455899 @default.
• W2153979476 cites W2132495825 @default.
• W2153979476 cites W2138297714 @default.
• W2153979476 cites W2139027674 @default.
• W2153979476 cites W2139248078 @default.
• W2153979476 cites W2139759135 @default.
• W2153979476 cites W2145683343 @default.
• W2153979476 cites W2158789700 @default.
• W2153979476 cites W2160403329 @default.
• W2153979476 cites W2167241562 @default.
• W2153979476 cites W2228803286 @default.
• W2153979476 doi "https://doi.org/10.1093/annonc/mds529" @default.
• W2153979476 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23129122" @default.
• W2153979476 hasPublicationYear "2013" @default.
• W2153979476 type Work @default.
• W2153979476 sameAs 2153979476 @default.
• W2153979476 citedByCount "208" @default.
• W2153979476 countsByYear W21539794762013 @default.
• W2153979476 countsByYear W21539794762014 @default.
• W2153979476 countsByYear W21539794762015 @default.
• W2153979476 countsByYear W21539794762016 @default.
• W2153979476 countsByYear W21539794762017 @default.
• W2153979476 countsByYear W21539794762018 @default.
• W2153979476 countsByYear W21539794762019 @default.
• W2153979476 countsByYear W21539794762020 @default.
• W2153979476 countsByYear W21539794762021 @default.
• W2153979476 countsByYear W21539794762022 @default.
• W2153979476 countsByYear W21539794762023 @default.
• W2153979476 crossrefType "journal-article" @default.
• W2153979476 hasAuthorship W2153979476A5004598929 @default.
• W2153979476 hasAuthorship W2153979476A5004928583 @default.
• W2153979476 hasAuthorship W2153979476A5006820907 @default.
• W2153979476 hasAuthorship W2153979476A5016049048 @default.
• W2153979476 hasAuthorship W2153979476A5019805104 @default.
• W2153979476 hasAuthorship W2153979476A5038306289 @default.
• W2153979476 hasAuthorship W2153979476A5043568223 @default.
• W2153979476 hasAuthorship W2153979476A5046162972 @default.
• W2153979476 hasAuthorship W2153979476A5047219755 @default.
• W2153979476 hasAuthorship W2153979476A5057704753 @default.
• W2153979476 hasAuthorship W2153979476A5074092905 @default.
• W2153979476 hasBestOaLocation W21539794761 @default.
• W2153979476 hasConcept C121608353 @default.
• W2153979476 hasConcept C126322002 @default.
• W2153979476 hasConcept C143998085 @default.
• W2153979476 hasConcept C197934379 @default.
• W2153979476 hasConcept C2776256026 @default.
• W2153979476 hasConcept C2776694085 @default.
• W2153979476 hasConcept C2777910003 @default.
• W2153979476 hasConcept C2778087573 @default.
• W2153979476 hasConcept C2778570526 @default.
• W2153979476 hasConcept C2778822529 @default.
• W2153979476 hasConcept C2779438470 @default.
• W2153979476 hasConcept C2779984678 @default.
• W2153979476 hasConcept C2780739268 @default.
• W2153979476 hasConcept C31760486 @default.
• W2153979476 hasConcept C71924100 @default.
• W2153979476 hasConcept C90924648 @default.
• W2153979476 hasConceptScore W2153979476C121608353 @default.
• W2153979476 hasConceptScore W2153979476C126322002 @default.
• W2153979476 hasConceptScore W2153979476C143998085 @default.

• next